Literature DB >> 34723044

All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages.

Enyu Rao1,2, Yuzhu Hou3,4, Xiaona Huang3, Liangliang Wang3, Jiaai Wang3, Wenxin Zheng3, Hengjin Yang1, Xinshuang Yu5, Kaiting Yang3, Jason Bugno6, Xingchen Ding7, Everett Vokes8, Yang-Xin Fu9, Ralph R Weichselbaum3, Hua L Liang3.   

Abstract

Radiotherapy (RT) is an important anti-cancer treatment modality that activates innate and adaptive immune responses. When all-trans retinoic acid (RA) was administered with radiation, we observed superior antitumor responses compared to ionizing radiation (IR) alone or RA alone. The superior antitumor effects of combination treatment were accompanied by a dramatic increase of TNF-α- and inducible nitric oxide synthase (iNOS)-producing inflammatory macrophages in local and distal non-irradiated (distal) tumors. Inflammatory macrophages are essential for the therapeutic efficacy of combination treatment by inducing effector T cell infiltration and enhancing the effector T cell to regulatory T cell ratio in local and distal tumors. T cells and T cell-derived IFN-γ are crucial for increasing inflammatory macrophage levels in IR and RA treated tumors. Notably, whereas CD8+ T cells are required for the antitumor response to IR, CD4+ T cells are required for the effectiveness of the IR and RA combination. Combination treatment with RA enhanced the abscopal response when radiation and PD-L1 blockade were used together. The synergistic positive feedback loop of inflammatory macrophages and adaptive immunity is required for the antitumor efficacy of IR plus RA combination treatment. Our findings provide a translational and relatively nontoxic strategy for enhancing the local and systemic antitumor effects of IR.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34723044      PMCID: PMC8550472          DOI: 10.1126/sciimmunol.aba8426

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  46 in total

Review 1.  Retinoids, retinoic acid receptors, and cancer.

Authors:  Xiao-Han Tang; Lorraine J Gudas
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

2.  Subversion of anticancer immunosurveillance by radiotherapy.

Authors:  Laurence Zitvogel; Guido Kroemer
Journal:  Nat Immunol       Date:  2015-10       Impact factor: 25.606

3.  Cancer stem cells and radiotherapy: new insights into tumor radioresistance.

Authors:  Maximilian Diehn; Michael F Clarke
Journal:  J Natl Cancer Inst       Date:  2006-12-20       Impact factor: 13.506

4.  Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy.

Authors:  Felix Klug; Hridayesh Prakash; Peter E Huber; Tobias Seibel; Noemi Bender; Niels Halama; Christina Pfirschke; Ralf Holger Voss; Carmen Timke; Ludmila Umansky; Kay Klapproth; Knut Schäkel; Natalio Garbi; Dirk Jäger; Jürgen Weitz; Hubertus Schmitz-Winnenthal; Günter J Hämmerling; Philipp Beckhove
Journal:  Cancer Cell       Date:  2013-10-24       Impact factor: 31.743

Review 5.  Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.

Authors:  Hugues de Thé; Pier Paolo Pandolfi; Zhu Chen
Journal:  Cancer Cell       Date:  2017-11-13       Impact factor: 31.743

6.  Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8+ T-cell immunity.

Authors:  Wei Yin; Yan Song; Qing Liu; Yunyun Wu; Rui He
Journal:  Immunology       Date:  2017-06-29       Impact factor: 7.397

7.  Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy.

Authors:  Yuzhu Hou; Hua Liang; Enyu Rao; Wenxin Zheng; Xiaona Huang; Liufu Deng; Yuan Zhang; Xinshuang Yu; Meng Xu; Helena Mauceri; Ainhoa Arina; Ralph R Weichselbaum; Yang-Xin Fu
Journal:  Immunity       Date:  2018-08-28       Impact factor: 31.745

8.  Human CD8⁺ T cells drive Th1 responses through the differentiation of TNF/iNOS-producing dendritic cells.

Authors:  Shu Zhen Chong; Kok Loon Wong; Gen Lin; Christopher Maolin Yang; Siew-Cheng Wong; Veronique Angeli; Paul A Macary; David Michael Kemeny
Journal:  Eur J Immunol       Date:  2011-05-09       Impact factor: 5.532

Review 9.  Regulation of iNOS on Immune Cells and Its Role in Diseases.

Authors:  Qingjie Xue; Yingchun Yan; Ruihua Zhang; Huabao Xiong
Journal:  Int J Mol Sci       Date:  2018-11-29       Impact factor: 5.923

10.  Clinical development of new drug-radiotherapy combinations.

Authors:  Ricky A Sharma; Ruth Plummer; Julie K Stock; Tessa A Greenhalgh; Ozlem Ataman; Stephen Kelly; Robert Clay; Richard A Adams; Richard D Baird; Lucinda Billingham; Sarah R Brown; Sean Buckland; Helen Bulbeck; Anthony J Chalmers; Glen Clack; Aaron N Cranston; Lars Damstrup; Roberta Ferraldeschi; Martin D Forster; Julian Golec; Russell M Hagan; Emma Hall; Axel-R Hanauske; Kevin J Harrington; Tom Haswell; Maria A Hawkins; Tim Illidge; Hazel Jones; Andrew S Kennedy; Fiona McDonald; Thorsten Melcher; James P B O'Connor; John R Pollard; Mark P Saunders; David Sebag-Montefiore; Melanie Smitt; John Staffurth; Ian J Stratford; Stephen R Wedge
Journal:  Nat Rev Clin Oncol       Date:  2016-06-01       Impact factor: 66.675

View more
  3 in total

Review 1.  (Im)maturity in Tumor Ecosystem.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Front Oncol       Date:  2022-01-25       Impact factor: 6.244

Review 2.  Irradiation immunity interactions.

Authors:  David A Simon Davis; Ines I Atmosukarto; Jessica Garrett; Katharine Gosling; Farhan M Syed; Ben Jc Quah
Journal:  J Med Imaging Radiat Oncol       Date:  2022-03-08       Impact factor: 1.667

Review 3.  Black phosphorous nanomaterials as a new paradigm for postoperative tumor treatment regimens.

Authors:  Yanhua Hou; Yang Fei; Zehong Liu; Yingqi Liu; Menghuan Li; Zhong Luo
Journal:  J Nanobiotechnology       Date:  2022-08-11       Impact factor: 9.429

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.